Neural Therapeutics Inc.
NURL
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.52% | -38.85% | -45.35% | -60.37% | -50.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.78% | -45.93% | -42.24% | -46.43% | -31.62% |
| Operating Income | 14.78% | 45.93% | 42.24% | 46.43% | 31.62% |
| Income Before Tax | -110.32% | 33.72% | 29.42% | 38.93% | 43.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -110.32% | 33.72% | 29.42% | 38.93% | 43.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.32% | 33.72% | 29.42% | 38.93% | 43.47% |
| EBIT | 14.78% | 45.93% | 42.24% | 46.43% | 31.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -41.49% | 55.56% | 52.00% | 58.50% | 56.07% |
| Normalized Basic EPS | 39.19% | 61.62% | 58.33% | 63.57% | 43.94% |
| EPS Diluted | -41.49% | 55.56% | 52.00% | 58.50% | 56.07% |
| Normalized Diluted EPS | 39.19% | 61.62% | 58.33% | 63.57% | 43.94% |
| Average Basic Shares Outstanding | 29.34% | 40.31% | 42.95% | 48.81% | 36.45% |
| Average Diluted Shares Outstanding | 29.34% | 40.31% | 42.95% | 48.81% | 36.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |